Clinical Trials
15 trialsNCT03922724 2026-05-22
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT05826535 2026-05-20
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Lyell Immunopharma, Inc.
Phase 1/2 Recruiting
NCT04996875 2026-05-05
APEX
Cogent Biosciences, Inc.
Phase 2 Recruiting
NCT07075185 2026-04-24
inMMyCAR
Kelonia Therapeutics, Inc.
Phase 1 Recruiting
NCT03328078 2026-04-16
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Phase 1/2 Recruiting
NCT07216443 2026-04-15
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Orca Biosystems, Inc.
Phase 2 Recruiting
NCT03207854 2026-04-02
Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers
University of Southern California
Recruiting
NCT05318196 2026-03-19
NEPHROGENE2
University Hospital, Toulouse
Recruiting
NCT05139706 2026-02-03
MIRAE
Sir Mortimer B. Davis - Jewish General Hospital
Recruiting
NCT05963217 2025-07-02
Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL
University Health Network, Toronto
Phase 1 Recruiting
NCT04104776 2025-05-15
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Novartis
Phase 1/2 Recruiting
NCT04658303 2025-05-08
Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma
University of Pittsburgh
Recruiting
NCT06644443 2024-10-16
BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma
Shenzhen University General Hospital
Phase 1/2 Recruiting
NCT04097067 2024-08-27
ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma
University Hospital Muenster
Phase NA Recruiting
NCT06271252 2024-08-02
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
OriCell Therapeutics Co., Ltd.
Phase 1 Recruiting